Quarterly report pursuant to Section 13 or 15(d)

REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS (Tables)

v3.22.1
REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS (Tables)
3 Months Ended
Mar. 31, 2022
REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS  
Schedule of disaggregation of net revenues

The Company’s net product revenues are summarized as follows:

​

​

​

​

​

​

​

​

​

    

Three-Month Periods Ended March 31, 

($ in thousands)

    

2022

    

2021

Qbrexa®

​

$

7,376

​

$

—

Accutane®

​

 

4,907

​

 

196

Amzeeq®

​

​

3,466

​

​

—

Targadox®

​

​

2,634

​

​

7,199

Ximino®

​

​

967

​

​

2,100

Zilxi®

​

​

741

​

​

—

Exelderm®

​

 

704

​

 

1,217

Other branded revenue

​

 

1

​

 

7

Total product revenues

​

$

20,796

​

$

10,719